A randomized, open-label, multicenter trial comparing once-a-day AVINZA® (morphine sulfate extended-release capsules) versus twice-a-day OxyContin® (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: Improved physical functioning in the ACTION trial
Keywords:morphine sulfate, oxycodone HCl, AVINZA, ACTION trial, low back pain, chronic pain, physicalfunctioning, quality of life
AbstractThis multicenter trial compared the efficacy, safety, and effect on quality of life and work limitation of once-daily extended-release morphine sulfate capsules (AVINZA9, A-MQD) and twice-daily controlled-release oxycodone HCl tablets (OxyContin9, O-ER) in subjects with chronic, moderate to severe low back pain. After randomization and a period of opioid dose titration, subjects (n = 266) underwent an eight-week evaluation phase and an optional four-month extension phase (n = 174 in extension phase). Subjects were assessed using the 12-item Short-Form Health Survey9 (SF-12) and the Work Limitations Questionnaire9 (WLQ). In both groups, significant improvements were observed in the SF-12 mean scores for physical functioning (p < 0.001), role physical (p < 0.0001), bodily pain (p < 0.0001), physical summary (p < 0.001), and mental component summary (p < 0.005). At the end of the titration period, greater relative improvements from baseline were seen in the SF-12 section on physical components in the A-MQD group versus the O-ER group, with significant differences observed for physical functioning (p = 0.0374), role physical (p = 0.0341), bodily pain (p = 0.0001), and physical summary (p = 0.0022). In both groups, SF-12 mean scores improved significantly for mental health (p < 0.01), role emotional (p < 0.01), social functioning (p < 0.0005), vitality (p < 0.005), and the mental component summary (p < 0.005), but no significant differences were noted between the two groups. Both groups reported improvement from baseline in WLQ physical demands scores, with no significant differences noted between the two groups. At the end of the evaluation phase, fewer subjects were unable to work due to illness or treatment in the A-MQD group than in the OER group (8.5percent versus 19.4percent, respectively; p = 0.0149). In conclusion, compared to twice-daily OxyContin, once-daily AVINZA resulted in significantly better and earlier improvement of physical function and ability to work.
Rauck RL, Bookbinder SA, Bunker TR, et al.: The ACTION Study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA®) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin®) for the treatment of chronic, moderate to severe low back pain. J OpioidManag. 2006; 2(3): 155-166.
Rauck RL, Bookbinder SA, Bunker TR, et al.: A randomized, open-label study of once-a-day AVINZA® (morphine sulfate extended-release capsules) versus twice-a-day OxyContin® (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: The extension phase of the ACTION trial. J OpioidManag. 2006; 2(6): 325-333.
Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3): 220-233.
Lerner D, Amick BC, Rogers WH, et al.: The Work Limitations Questionnaire. Med Care. 2001; 39(1): 72-85.
Luo X, Pietrobon R, Sun SX, et al.: Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine. 2004; 29(1): 79-86.
Allan DB, Waddell G: A historical perspective on low back pain and disability. Acta Orthop Scand. 1989; 60(Suppl 234): 1-23.
Moulin DE: Systemic drug treatment for chronic musculoskeletal pain. Clin J Pain. 2001; 17(4 Suppl): S86-S93.
Moulin DE, Iezzi A, Amireh R, et al.: Randomised trial of oral mor-phine for chronic non-cancer pain. Lancet. 1996; 347(8995): 143-147.
McCarberg BH, Barkin RL: Long-acting opioids for chronic pain: Pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001; 8(3): 181-186.
Peloso PM, Bellamy N, Bensen W, et al.: Double-blind randomized placebo-controlled trial of controlled-release codeine in the treatment of osteoarthritis of the hip and knee. J Rheumatol. 2000; 27: 764-771.
Dworkin RH, Turk DC, Farrar JT, et al.: Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005; 113(1-2): 9-19.
Caldwell JR, Rapoport RJ, Davis JC, et al.: Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebocontrolled, double-blind trial and an open-label extension trial. J Pain Symptom Manage. 2002; 23(4): 278-291.
Adams EH, Chwiecko P, Ace-Wagoner Y, et al.: A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions—The ACCPT Study. Pain Pract. 2006; 6(4): 254-264.
Nicholson B, Ross E, Sasaki J, et al.: Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr Med Res Op. 2006; 22(8): 1503-1514.
How to Cite
Copyright 2005-2023, Weston Medical Publishing, LLC
All Rights Reserved